Kyohei Yamaji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyohei Yamaji has a total of 415 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Ando
Kokura Memorial Hospital
17 shared publications Kenji Ando
Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan
16 shared publications- Hideki Ishii
Department of Cardiovascular medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
14 shared publications Kazushige Kadota
Department of Cardiology Kurashiki Central Hospital Kurashiki Japan
14 shared publications- Shun Kohsaka
Keio University School of Medicine
12 shared publications - Takeshi Kimura
Department of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan
11 shared publications
Latest Publications
- Open Access
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e041252
Left‐Digit Bias in Serum Creatinine Levels and Contrast Administration: A Nationwide Cohort Study Using a Japanese Percutaneous Coronary Intervention Registry
Background: Contemporary quality initiatives emphasize minimizing contrast volume as a key modifiable factor to prevent acute kidney injury (AKI) following percutaneous coronary intervention (PCI). Left‐digit bias is a cognitive bias where the leftmost digit of a number disproportionately influences decisions. This bias may unintentionally affect contrast administration when interpreting laboratory values like serum creatinine. Therefore, we aim to assess the impact of left‐digit bias in serum creatinine level on contrast volume in PCI. Methods: We analyzed patients undergoing PCI between January 2018 and December 2022 using the Japanese nationwide prospective multicenter registry. The primary outcome was PCI contrast volume. Left‐digit bias was assessed by comparing contrast volume differences at specific creatinine thresholds (eg, 1.0 mg/dL and 2.0 mg/dL). AKI risks were calculated by a validated risk scoring system. Results: Among 735 696 PCI procedures, the median contrast volume was 117 mL (interquartile range 85–157 mL). Analysis of average contrast volume revealed a sharp decrease at baseline creatinine levels above versus less than 1 mg/dL (mean difference, 2.2 mL [95% CI, 1.6–2.8]) and 2 mg/dL (4.7 [95% CI, 1.6–7.8]) but not at 3 mg/dL (−2.0 [95% CI, −10.0 to 6.0]). Despite differences at integer thresholds of creatinine, minimal variation across AKI risk levels suggests operators prioritize creatinine values over predicted AKI risk. Conclusions: Our study provides valuable insights into contemporary trends in contrast volume for PCI and identifies left‐digit bias in creatinine interpretation affecting contrast administration. Formal risk stratification is essential to optimize contrast use for AKI prevention.
- 15 July 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (14) , e041252
Open AccessLeft‐Digit Bias in Serum Creatinine Levels and Contrast Administration: A Nationwide Cohort Study Using a Japanese Percutaneous Coronary Intervention Registry
Background: Contemporary quality initiatives emphasize minimizing contrast volume as a key modifiable factor to prevent acute kidney injury (AKI) following percutaneous coronary intervention (PCI). Left‐digit bias is a cognitive bias where the leftmost digit of a number disproportionately influences decisions. This bias may unintentionally affect contrast administration when interpreting laboratory values like serum creatinine. Therefore, we aim to assess the impact of left‐digit bias in serum creatinine level on contrast volume in PCI. Methods: We analyzed patients undergoing PCI between January 2018 and December 2022 using the Japanese nationwide prospective multicenter registry. The primary outcome was PCI contrast volume. Left‐digit bias was assessed by comparing contrast volume differences at specific creatinine thresholds (eg, 1.0 mg/dL and 2.0 mg/dL). AKI risks were calculated by a validated risk scoring system. Results: Among 735 696 PCI procedures, the median contrast volume was 117 mL (interquartile range 85–157 mL). Analysis of average contrast volume revealed a sharp decrease at baseline creatinine levels above versus less than 1 mg/dL (mean difference, 2.2 mL [95% CI, 1.6–2.8]) and 2 mg/dL (4.7 [95% CI, 1.6–7.8]) but not at 3 mg/dL (−2.0 [95% CI, −10.0 to 6.0]). Despite differences at integer thresholds of creatinine, minimal variation across AKI risk levels suggests operators prioritize creatinine values over predicted AKI risk. Conclusions: Our study provides valuable insights into contemporary trends in contrast volume for PCI and identifies left‐digit bias in creatinine interpretation affecting contrast administration. Formal risk stratification is essential to optimize contrast use for AKI prevention.
- Open Access
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e038071
Successful or Uncomplicated Use of Drug‐Coated Balloon Versus Drug‐Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan
Background: Randomized trials demonstrated that drug‐coated balloon (DCB) was not inferior to drug‐eluting stent (DES) for acute coronary syndrome (ACS). However, generalizability in clinical settings remains unclear. The present study compared the outcomes of DCB and DES strategies in percutaneous coronary intervention for ACS within a nationwide procedure‐based registry. Methods and Results: This was a retrospective analysis of a cohort study from a prospective, nationwide registry between January 2017 and December 2020 in Japan, focusing on patients with ACS who underwent DCB or DES for a single de novo lesion. Patients who required bailout stenting after treatment with DCB were excluded from the analysis. The 1‐year incidence of all‐cause mortality, cardiovascular death, noncardiovascular death, nonfatal ACS, stroke, and major bleeding events was compared. A subgroup analysis included lesion‐based and ST‐elevation myocardial infarction/non‐ST‐elevation ACS stratifications. Among 5212 propensity score–matched patients with ACS, no significant differences were observed in the 1‐year incidence of all‐cause mortality (4.5% versus 4.6%, hazard ratio [HR], 0.92 [95% CI, 0.72–1.19]); cardiovascular death (2.5% versus 2.5%, HR, 0.90 [95% CI, 0.64–1.26]); noncardiovascular death (2.0% versus 2.1%, HR, 0.96 [95% CI, 0.65–1.42]); or nonfatal ACS (1.7% versus 2.0%, HR, 1.04 [95% CI, 0.70–1.54]) between DCB and DES. DCB was associated with a higher incidence of stroke (0.8% versus 0.3%, HR, 2.33 [95% CI, 1.06–5.08]) and lower incidence of major bleeding events (1.4% versus 2.3%, HR, 0.65 [95% CI, 0.43–0.99]); however, these results were not reproduced in the subgroup analysis. Conclusions: The DCB strategy for successfully treated ACS cases achieved similar clinical outcomes to DES after 1 year. Further studies with an extended follow‐up are needed to confirm these results.
- 3 June 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (11) , e038071
Open AccessSuccessful or Uncomplicated Use of Drug‐Coated Balloon Versus Drug‐Eluting Stent Strategies for De Novo Culprit Lesions in Acute Coronary Syndromes: Insights from a Nationwide Registry in Japan
Background: Randomized trials demonstrated that drug‐coated balloon (DCB) was not inferior to drug‐eluting stent (DES) for acute coronary syndrome (ACS). However, generalizability in clinical settings remains unclear. The present study compared the outcomes of DCB and DES strategies in percutaneous coronary intervention for ACS within a nationwide procedure‐based registry. Methods and Results: This was a retrospective analysis of a cohort study from a prospective, nationwide registry between January 2017 and December 2020 in Japan, focusing on patients with ACS who underwent DCB or DES for a single de novo lesion. Patients who required bailout stenting after treatment with DCB were excluded from the analysis. The 1‐year incidence of all‐cause mortality, cardiovascular death, noncardiovascular death, nonfatal ACS, stroke, and major bleeding events was compared. A subgroup analysis included lesion‐based and ST‐elevation myocardial infarction/non‐ST‐elevation ACS stratifications. Among 5212 propensity score–matched patients with ACS, no significant differences were observed in the 1‐year incidence of all‐cause mortality (4.5% versus 4.6%, hazard ratio [HR], 0.92 [95% CI, 0.72–1.19]); cardiovascular death (2.5% versus 2.5%, HR, 0.90 [95% CI, 0.64–1.26]); noncardiovascular death (2.0% versus 2.1%, HR, 0.96 [95% CI, 0.65–1.42]); or nonfatal ACS (1.7% versus 2.0%, HR, 1.04 [95% CI, 0.70–1.54]) between DCB and DES. DCB was associated with a higher incidence of stroke (0.8% versus 0.3%, HR, 2.33 [95% CI, 1.06–5.08]) and lower incidence of major bleeding events (1.4% versus 2.3%, HR, 0.65 [95% CI, 0.43–0.99]); however, these results were not reproduced in the subgroup analysis. Conclusions: The DCB strategy for successfully treated ACS cases achieved similar clinical outcomes to DES after 1 year. Further studies with an extended follow‐up are needed to confirm these results.
- Open Access
- 5 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e034458
Serial Optical Coherence Tomography Assessment of Coronary Atherosclerosis and Long‐Term Clinical Outcomes
Background: The impact of high‐risk coronary artery plaques identified using optical coherence tomography on late luminal narrowing and clinical events remains poorly understood. Methods and Results: This multicenter prospective study included 176 patients who underwent percutaneous coronary intervention and serial optical coherence tomography at baseline and 1‐year follow‐up to investigate nontarget regions with angiographically intermediate stenosis. At 1 year after percutaneous coronary intervention, the coronary artery lumen area decreased significantly from 6.06 (95% CI, 5.60–6.53) mm 2 to 5.88 (95% CI, 5.41–6.35) mm 2 (difference, −0.18; 95% CI, −0.22 to −0.14 mm 2 ; P P P P =0.04), primarily due to revascularization in the imaged region. No significant association was observed between coronary artery calcium prevalence and clinical outcomes within 3 years. Conclusions: The coronary artery lumen area significantly decreased over a 1‐year interval, particularly in thin‐cap fibroatheromas, thick‐cap fibroatheromas, mixed plaques, and fibrous plaques. Although thin‐cap fibroatheroma prevalence was associated with higher risk of ischemia‐driven nontarget vessel revascularization, no significant association was noted between coronary artery calcium prevalence and clinical outcomes within 3 years. The interaction between calcium progression and long‐term clinical events necessitates further investigation. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique Identifier: UMIN000031937.
- 5 November 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e034458
Open AccessSerial Optical Coherence Tomography Assessment of Coronary Atherosclerosis and Long‐Term Clinical Outcomes
Background: The impact of high‐risk coronary artery plaques identified using optical coherence tomography on late luminal narrowing and clinical events remains poorly understood. Methods and Results: This multicenter prospective study included 176 patients who underwent percutaneous coronary intervention and serial optical coherence tomography at baseline and 1‐year follow‐up to investigate nontarget regions with angiographically intermediate stenosis. At 1 year after percutaneous coronary intervention, the coronary artery lumen area decreased significantly from 6.06 (95% CI, 5.60–6.53) mm 2 to 5.88 (95% CI, 5.41–6.35) mm 2 (difference, −0.18; 95% CI, −0.22 to −0.14 mm 2 ; P P P P =0.04), primarily due to revascularization in the imaged region. No significant association was observed between coronary artery calcium prevalence and clinical outcomes within 3 years. Conclusions: The coronary artery lumen area significantly decreased over a 1‐year interval, particularly in thin‐cap fibroatheromas, thick‐cap fibroatheromas, mixed plaques, and fibrous plaques. Although thin‐cap fibroatheroma prevalence was associated with higher risk of ischemia‐driven nontarget vessel revascularization, no significant association was noted between coronary artery calcium prevalence and clinical outcomes within 3 years. The interaction between calcium progression and long‐term clinical events necessitates further investigation. Registration: URL: https://www.umin.ac.jp/ctr/ ; Unique Identifier: UMIN000031937.
- 11 June 2024
- Published by Elsevier in Journal of Cardiology
- Vol. 84 (4) , 300-310
Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; a report from the CREDO-Kyoto registry
- 11 June 2024
- Published by Elsevier in Journal of Cardiology
- Vol. 84 (4) , 300-310
Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; a report from the CREDO-Kyoto registry
- Open Access
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e031838
Changing Trends in Mechanical Circulatory Support Use and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndrome Complicated With Cardiogenic Shock: Insights From a Nationwide Registry in Japan
Background: Temporal trends in the management of acute coronary syndrome complicated with cardiogenic shock after the revision of guideline recommendations for intra‐aortic balloon pump (IABP) use and the approval of the Impella require further investigation, because their impact remains uncertain. Methods and Results: Using the Japanese Percutaneous Coronary Intervention (J‐PCI) registry database from 2019 to 2021, we identified 12 171 patients undergoing percutaneous coronary intervention for acute coronary syndrome complicated with cardiogenic shock under mechanical circulatory support. The patients were stratified into 3 groups: (1) IABP alone, (2) Impella, and (3) venoarterial extracorporeal membrane oxygenation (VA‐ECMO); the VA‐ECMO group was further stratified into (3a) VA‐ECMO alone, (3b) VA‐ECMO in combination with IABP, and (3c) VA‐ECMO in combination with Impella. The quarterly prevalence and outcomes were reported. The use of IABP alone decreased significantly from 63.5% in the first quarter of 2019 to 58.3% in the fourth quarter of 2021 ( P for trend=0.01). Among 4245 patients requiring VA‐ECMO, the use of VA‐ECMO in combination with IABP decreased significantly from 78.7% to 67.3%, whereas the use of VA‐ECMO in combination with Impella increased significantly from 4.2% to 17.0% ( P for trend <0.001 for both). After adjusting for the confounders, the risk difference in the fourth quarter of 2021 relative to the first quarter of 2019 for in‐hospital mortality was not significant (adjusted odds ratio, 0.84 [95% CI, 0.69–1.01]). Conclusions: Our study revealed substantial changes in the use of different mechanical circulatory support modalities in acute coronary syndrome complicated with cardiogenic shock, but they did not significantly improve the outcomes.
- 5 December 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (23) , e031838
Open AccessChanging Trends in Mechanical Circulatory Support Use and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndrome Complicated With Cardiogenic Shock: Insights From a Nationwide Registry in Japan
Background: Temporal trends in the management of acute coronary syndrome complicated with cardiogenic shock after the revision of guideline recommendations for intra‐aortic balloon pump (IABP) use and the approval of the Impella require further investigation, because their impact remains uncertain. Methods and Results: Using the Japanese Percutaneous Coronary Intervention (J‐PCI) registry database from 2019 to 2021, we identified 12 171 patients undergoing percutaneous coronary intervention for acute coronary syndrome complicated with cardiogenic shock under mechanical circulatory support. The patients were stratified into 3 groups: (1) IABP alone, (2) Impella, and (3) venoarterial extracorporeal membrane oxygenation (VA‐ECMO); the VA‐ECMO group was further stratified into (3a) VA‐ECMO alone, (3b) VA‐ECMO in combination with IABP, and (3c) VA‐ECMO in combination with Impella. The quarterly prevalence and outcomes were reported. The use of IABP alone decreased significantly from 63.5% in the first quarter of 2019 to 58.3% in the fourth quarter of 2021 ( P for trend=0.01). Among 4245 patients requiring VA‐ECMO, the use of VA‐ECMO in combination with IABP decreased significantly from 78.7% to 67.3%, whereas the use of VA‐ECMO in combination with Impella increased significantly from 4.2% to 17.0% ( P for trend <0.001 for both). After adjusting for the confounders, the risk difference in the fourth quarter of 2021 relative to the first quarter of 2019 for in‐hospital mortality was not significant (adjusted odds ratio, 0.84 [95% CI, 0.69–1.01]). Conclusions: Our study revealed substantial changes in the use of different mechanical circulatory support modalities in acute coronary syndrome complicated with cardiogenic shock, but they did not significantly improve the outcomes.
- Open Access
- 7 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (21) , e030881
Age‐Stratified Prevalence and Relative Prognostic Significance of Traditional Atherosclerotic Risk Factors: A Report from the Nationwide Registry of Percutaneous Coronary Interventions in Japan
Background: The prevalence of traditional atherosclerotic risk factors (TARFs) and their association with clinical profiles or mortality in percutaneous coronary intervention remain unclear. Methods and Results: The study analyzed 559 452 patients who underwent initial percutaneous coronary intervention between 2012 and 2019 in Japan. TARFs were defined as male sex, hypertension, dyslipidemia, diabetes, smoking, and chronic kidney disease. We calculated the relative importance according to R 2 and machine learning models to assess the impact of TARFs on clinical profile and in‐hospital mortality. The relative contribution (RC) of each TARF was defined as the average percentage of the relative importance calculated from these models. The age‐specific prevalence of TARFs, except for chronic kidney disease, formed an inverted U‐shape with significantly different peaks and percentages. In the logistic regression model and relative risk model, smoking was most strongly associated with acute myocardial infarction (adjusted odds ratio [OR], 1.62 [95% CI, 1.60–1.64]; RC, 47.1%) and premature coronary artery disease (adjusted unstandardized beta coefficient, 2.68 [95% CI, 2.65–2.71], RC, 42.2%). Diabetes was most strongly associated with multivessel disease (adjusted unstandardized beta coefficient, 0.068 [95% CI, 0.066–0.070], RC, 59.4%). The absence of dyslipidemia was most strongly associated with presentation of cardiogenic shock (adjusted OR, 0.62 [95% CI, 0.61–0.64], RC, 34.2%) and in‐hospital mortality (adjusted OR, 0.44 [95% CI, 0.41–0.46], RC, 39.8%). These specific associations were consistently observed regardless of adjustment or stratification by age. Conclusions: Our analysis showed a significant variation in the age‐specific prevalence of TARFs. Further, their contribution to clinical profiles and mortality also varied widely.
- 7 November 2023
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 12 (21) , e030881
Open AccessAge‐Stratified Prevalence and Relative Prognostic Significance of Traditional Atherosclerotic Risk Factors: A Report from the Nationwide Registry of Percutaneous Coronary Interventions in Japan
Background: The prevalence of traditional atherosclerotic risk factors (TARFs) and their association with clinical profiles or mortality in percutaneous coronary intervention remain unclear. Methods and Results: The study analyzed 559 452 patients who underwent initial percutaneous coronary intervention between 2012 and 2019 in Japan. TARFs were defined as male sex, hypertension, dyslipidemia, diabetes, smoking, and chronic kidney disease. We calculated the relative importance according to R 2 and machine learning models to assess the impact of TARFs on clinical profile and in‐hospital mortality. The relative contribution (RC) of each TARF was defined as the average percentage of the relative importance calculated from these models. The age‐specific prevalence of TARFs, except for chronic kidney disease, formed an inverted U‐shape with significantly different peaks and percentages. In the logistic regression model and relative risk model, smoking was most strongly associated with acute myocardial infarction (adjusted odds ratio [OR], 1.62 [95% CI, 1.60–1.64]; RC, 47.1%) and premature coronary artery disease (adjusted unstandardized beta coefficient, 2.68 [95% CI, 2.65–2.71], RC, 42.2%). Diabetes was most strongly associated with multivessel disease (adjusted unstandardized beta coefficient, 0.068 [95% CI, 0.066–0.070], RC, 59.4%). The absence of dyslipidemia was most strongly associated with presentation of cardiogenic shock (adjusted OR, 0.62 [95% CI, 0.61–0.64], RC, 34.2%) and in‐hospital mortality (adjusted OR, 0.44 [95% CI, 0.41–0.46], RC, 39.8%). These specific associations were consistently observed regardless of adjustment or stratification by age. Conclusions: Our analysis showed a significant variation in the age‐specific prevalence of TARFs. Further, their contribution to clinical profiles and mortality also varied widely.
- Open Access
- 3 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 3 (6) , oead116
Transradial intervention in dialysis patients undergoing percutaneous coronary intervention: a Japanese nationwide registry study
Transradial intervention (TRI) for percutaneous coronary intervention (PCI) is used to reduce periprocedural complications. However, its effectiveness and safety for patients on dialysis are not well established. We aimed to investigate the association of TRI with in-hospital complications in dialysis patients undergoing PCI. We included 44 462 patients on dialysis who underwent PCI using Japanese nationwide PCI registry data (2019–21) regardless of acute or chronic coronary syndrome. Patients were categorized based on access site: TRI, transfemoral intervention (TFI). Periprocedural access site bleeding complication requiring transfusion was the primary outcome and in-hospital death, and other periprocedural complications were the secondary outcomes. Matched weighted analysis was performed for TRI and TFI. Here, 8267 (18.6%) underwent TRI, and 36 195 (81.4%) underwent TFI. Patients who received TRI were older and had lower rates of comorbidities than those who received TFI. Access site bleeding rate and in-hospital death were significantly lower in the TRI group (0.1% vs. 0.7%, P < 0.001; 1.8% vs. 3.2%, P < 0.001, respectively). After adjustment, TRI was associated with a lower risk of access site bleeding (odds ratio [OR] [95% confidence interval (CI)]: 0.19 [0.099–0.38]; P < 0.001) and in-hospital death (OR [95% CI]: 0.79 [0.65–0.96]; P = 0.02). Other periprocedural complications between TRI and TFI were not significantly different. In patients undergoing dialysis and PCI, TRI had a lower risk of access site bleeding and in-hospital death than TFI. This suggests that TRI may be safer for this patient population. Forest plots of adjusted odds ratios for in-hospital death and bleeding events. Bars represent confidence intervals of odds ratios. OR, odds ratio; PCI, percutaneous coronary intervention; TRI, transradial intervention.
- 3 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 3 (6) , oead116
Open AccessTransradial intervention in dialysis patients undergoing percutaneous coronary intervention: a Japanese nationwide registry study
Transradial intervention (TRI) for percutaneous coronary intervention (PCI) is used to reduce periprocedural complications. However, its effectiveness and safety for patients on dialysis are not well established. We aimed to investigate the association of TRI with in-hospital complications in dialysis patients undergoing PCI. We included 44 462 patients on dialysis who underwent PCI using Japanese nationwide PCI registry data (2019–21) regardless of acute or chronic coronary syndrome. Patients were categorized based on access site: TRI, transfemoral intervention (TFI). Periprocedural access site bleeding complication requiring transfusion was the primary outcome and in-hospital death, and other periprocedural complications were the secondary outcomes. Matched weighted analysis was performed for TRI and TFI. Here, 8267 (18.6%) underwent TRI, and 36 195 (81.4%) underwent TFI. Patients who received TRI were older and had lower rates of comorbidities than those who received TFI. Access site bleeding rate and in-hospital death were significantly lower in the TRI group (0.1% vs. 0.7%, P < 0.001; 1.8% vs. 3.2%, P < 0.001, respectively). After adjustment, TRI was associated with a lower risk of access site bleeding (odds ratio [OR] [95% confidence interval (CI)]: 0.19 [0.099–0.38]; P < 0.001) and in-hospital death (OR [95% CI]: 0.79 [0.65–0.96]; P = 0.02). Other periprocedural complications between TRI and TFI were not significantly different. In patients undergoing dialysis and PCI, TRI had a lower risk of access site bleeding and in-hospital death than TFI. This suggests that TRI may be safer for this patient population. Forest plots of adjusted odds ratios for in-hospital death and bleeding events. Bars represent confidence intervals of odds ratios. OR, odds ratio; PCI, percutaneous coronary intervention; TRI, transradial intervention.
- Open Access
Prognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; A report from the CREDO-Kyoto registry
Background: The impact of very low baseline levels of low-density lipoprotein cholesterol (LDL-C) on patients with coronary artery disease remains unclear. Therefore, we aimed to investigate the baseline characteristics and clinical outcomes of patients with low baseline LDL-C levels who had undergone coronary revascularization. Methods: We enrolled 39439 patients of the pooled population from the CREDO-Kyoto registries Cohorts 1, 2, and 3. After excluding 6306 patients with missing baseline LDL-C data, the study population consisted of 33133 patients who had undergone their first coronary revascularization. We assessed the risk for mortality and cardiovascular events according to quintiles of the baseline LDL-C levels. Results: Patients in the very low LDL-C quintile (< 85 mg/dL) had more comorbidities than those in the other quintiles. Lower LDL-C levels were strongly associated with anemia, thrombocytopenia, and end-stage renal disease. The cumulative 4-year incidence of all-cause death increased as LDL-C levels decreased (very low: 19.4%, low: 14.5%, intermediate: 11.1%, high: 10.0%, and very high:9.2%; P<0.001), which was driven by both the early and late events. After adjusting for baseline characteristics, the adjusted risks of the very low and low LDL-C quintiles relative to the intermediate LDL-C quintile remained significant for all-cause death (very low: HR 1.29, 95% CI 1.16-1.44, P<0.001; low: HR 1.15, 95% CI 1.03-1.29, P=0.01). There were no significant interactions between the association of LDL-C level with all-cause death and subgroup factors, such as lipid-lowering treatment at index hospitalization, age, sex, acute myocardial infarction presentation, and study cohort. The excess adjusted risks of the lowest LDL-C quintile relative to the intermediate LDL-C quintile were significant for clinical outcomes such as cardiovascular death (HR 1.17, 95% CI 1.01-1.35), non-cardiovascular death (HR 1.35, 95% CI 1.15-1.60), sudden death (HR 1.44, 95% CI 1.01-2.06), and heart failure admission (HR 1.11 95% CI 1.01-1.22), while there was no excess risk for the lowest LDL-C quintile relative to the intermediate LDL-C quintile for myocardial infarction and stroke. Conclusions: Lower baseline LDL-C levels were associated with more comorbidities and a significantly higher risk of death, regardless of cardiovascular or non-cardiovascular causes, in patients who underwent coronary revascularization.
Open AccessPrognostic significance of baseline low-density lipoprotein cholesterol in patients undergoing coronary revascularization; A report from the CREDO-Kyoto registry
Background: The impact of very low baseline levels of low-density lipoprotein cholesterol (LDL-C) on patients with coronary artery disease remains unclear. Therefore, we aimed to investigate the baseline characteristics and clinical outcomes of patients with low baseline LDL-C levels who had undergone coronary revascularization. Methods: We enrolled 39439 patients of the pooled population from the CREDO-Kyoto registries Cohorts 1, 2, and 3. After excluding 6306 patients with missing baseline LDL-C data, the study population consisted of 33133 patients who had undergone their first coronary revascularization. We assessed the risk for mortality and cardiovascular events according to quintiles of the baseline LDL-C levels. Results: Patients in the very low LDL-C quintile (< 85 mg/dL) had more comorbidities than those in the other quintiles. Lower LDL-C levels were strongly associated with anemia, thrombocytopenia, and end-stage renal disease. The cumulative 4-year incidence of all-cause death increased as LDL-C levels decreased (very low: 19.4%, low: 14.5%, intermediate: 11.1%, high: 10.0%, and very high:9.2%; P<0.001), which was driven by both the early and late events. After adjusting for baseline characteristics, the adjusted risks of the very low and low LDL-C quintiles relative to the intermediate LDL-C quintile remained significant for all-cause death (very low: HR 1.29, 95% CI 1.16-1.44, P<0.001; low: HR 1.15, 95% CI 1.03-1.29, P=0.01). There were no significant interactions between the association of LDL-C level with all-cause death and subgroup factors, such as lipid-lowering treatment at index hospitalization, age, sex, acute myocardial infarction presentation, and study cohort. The excess adjusted risks of the lowest LDL-C quintile relative to the intermediate LDL-C quintile were significant for clinical outcomes such as cardiovascular death (HR 1.17, 95% CI 1.01-1.35), non-cardiovascular death (HR 1.35, 95% CI 1.15-1.60), sudden death (HR 1.44, 95% CI 1.01-2.06), and heart failure admission (HR 1.11 95% CI 1.01-1.22), while there was no excess risk for the lowest LDL-C quintile relative to the intermediate LDL-C quintile for myocardial infarction and stroke. Conclusions: Lower baseline LDL-C levels were associated with more comorbidities and a significantly higher risk of death, regardless of cardiovascular or non-cardiovascular causes, in patients who underwent coronary revascularization.
- Open Access
Changing Trends in Mechanical Circulatory Support Utilization and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndrome Complicated with Cardiogenic Shock: Insights from a Nationwide Registry in Japan
Background: Temporal trends in the management of acute coronary syndrome (ACS) complicated with cardiogenic shock (CS) after the revision of the guideline recommendations for intra-aortic balloon pump (IABP) use and the approval of the Impella require further investigation as their impact remains uncertain. Methods: Using the Japanese Percutaneous Coronary Intervention (J-PCI) registry database from 2019 to 2021 (734,379 patients from 1,190 hospitals), we extracted 24,516 patients undergoing PCI for ACS complicated with CS. Of those, 12,171 patients (49.6%) used mechanical circulatory support (MCS) during the procedure. The patients were stratified into three groups: (i) IABP alone, (ii) Impella, and (iii) venoarterial extracorporeal membrane oxygenation (VA-ECMO); the VA-ECMO group was further stratified into (iiia) VA-ECMO alone, (iiib) VA-ECMO in combination with the IABP, and (iiic) VA-ECMO in combination with the Impella (ECPella). The quarterly prevalence and outcomes were reported. Results: During the study period, there were notable changes in the prevalence of different MCS modalities and their associated outcomes. The use of an IABP alone and VA-ECMO decreased significantly from 63.5% and 34.4% in the first quarter of 2019 to 58.3% and 33.0% in the fourth quarter of 2021, respectively (P for trend = 0.01 and 0.02, respectively). Among the subset of patients who required VA-ECMO ( n = 4,245), the use of VA-ECMO in combination with the IABP decreased significantly from 78.7% to 67.3%, whereas the use of ECPella increased significantly from 4.2% to 17.0% (P for trend <0.001 for both). There was no significant change in the use of VA-ECMO alone. In-hospital mortality decreased significantly over time in both the overall population of patients requiring MCS and those requiring VA-ECMO (P for trend = 0.004 and <0.001, respectively). Conclusions: In conclusion, our study revealed significant changes in the use of different MCS modalities and associated outcomes in ACS complicated with CS, highlighting the evolving patterns of MCS utilization during the study period.
Open AccessChanging Trends in Mechanical Circulatory Support Utilization and Outcomes in Patients Undergoing Percutaneous Coronary Interventions for Acute Coronary Syndrome Complicated with Cardiogenic Shock: Insights from a Nationwide Registry in Japan
Background: Temporal trends in the management of acute coronary syndrome (ACS) complicated with cardiogenic shock (CS) after the revision of the guideline recommendations for intra-aortic balloon pump (IABP) use and the approval of the Impella require further investigation as their impact remains uncertain. Methods: Using the Japanese Percutaneous Coronary Intervention (J-PCI) registry database from 2019 to 2021 (734,379 patients from 1,190 hospitals), we extracted 24,516 patients undergoing PCI for ACS complicated with CS. Of those, 12,171 patients (49.6%) used mechanical circulatory support (MCS) during the procedure. The patients were stratified into three groups: (i) IABP alone, (ii) Impella, and (iii) venoarterial extracorporeal membrane oxygenation (VA-ECMO); the VA-ECMO group was further stratified into (iiia) VA-ECMO alone, (iiib) VA-ECMO in combination with the IABP, and (iiic) VA-ECMO in combination with the Impella (ECPella). The quarterly prevalence and outcomes were reported. Results: During the study period, there were notable changes in the prevalence of different MCS modalities and their associated outcomes. The use of an IABP alone and VA-ECMO decreased significantly from 63.5% and 34.4% in the first quarter of 2019 to 58.3% and 33.0% in the fourth quarter of 2021, respectively (P for trend = 0.01 and 0.02, respectively). Among the subset of patients who required VA-ECMO ( n = 4,245), the use of VA-ECMO in combination with the IABP decreased significantly from 78.7% to 67.3%, whereas the use of ECPella increased significantly from 4.2% to 17.0% (P for trend <0.001 for both). There was no significant change in the use of VA-ECMO alone. In-hospital mortality decreased significantly over time in both the overall population of patients requiring MCS and those requiring VA-ECMO (P for trend = 0.004 and <0.001, respectively). Conclusions: In conclusion, our study revealed significant changes in the use of different MCS modalities and associated outcomes in ACS complicated with CS, highlighting the evolving patterns of MCS utilization during the study period.
- Open Access
Age-stratified Prevalence and Relative Prognostic Significance of Traditional Atherosclerotic Risk Factors: A Report from the Nationwide Registry of Percutaneous Coronary Interventions in Japan
Background: The prevalence of traditional atherosclerotic risk factors (TARFs) and their association with clinical profiles or mortality in percutaneous coronary intervention (PCI) remain unclear. Methods: The study analyzed 559,452 patients who underwent initial PCI between 2012 and 2019 in Japan. TARFs were defined male, hypertension, dyslipidemia, diabetes, smoking, and chronic kidney disease (CKD). We evaluated the age-specific prevalence of TARFs, and calculated the relative importance (RI) according to R 2 , machine learning to assess the impact of TARFs on clinical profile (age, the presentation of acute myocardial infarction, cardiogenic shock, and multivessel disease) and in-hospital mortality. The average percentage of the RI calculated from these models was defined as the relative contribution (RC) of each TARF. Results: The age-specific prevalence of TARFs, except for CKD, formed an inverted U-shape with significantly different peaks and percentages. Smoking was more prevalent in patients with ST-elevation myocardial infarction than in patients with stable angina (odds ratio [OR], 1.75, 95% confidence interval [CI], 1.73-1.77). In logistic regression model and relative risk model, smoking was most strongly associated with acute myocardial infarction (AMI) (adjusted OR, 1.62, 95% CI, 1.60-1.64; RC, 47.1%) and premature coronary artery disease (adjusted unstandardized beta coefficient [UC], 2.68, 95% CI, 2.65-2.71, RC, 42.2%). Diabetes was most strongly associated with multivessel disease (adjusted UC, 0.068; 95% CI, 0.066-0.070, RC, 59.4%) and the presentation of non-AMI (adjusted OR, 0.77, 95% CI, 0.76-0.78, RI, 21.9%). The absence of dyslipidemia was most strongly associated with presentation of cardiogenic shock (adjusted OR, 0.62; 95% CI, 0.61-0.64, RC, 34.2%) and in-hospital mortality (adjusted OR, 0.44, 95% CI, 0.41-0.46, RC, 39.8%). These specific associations were consistently observed regardless of adjustment or stratification by age. Conclusions: Our analysis showed a significant variation in the age-specific prevalence of TARFs. Further, their contribution to clinical profiles and mortality also varied widely. What is known: Traditional atherosclerotic risk factors (TARFs) are well-established targets for the prevention of adverse cardiovascular events. The impact of TARFs on clinical profiles in the patients with percutaneous coronary intervention remain unclear. What the Study Adds: Due to the prevalence of TARF, which varies by age group, the TARFs that should be actively intervened and educated on will differ for each age group The relative importance of TARF differed significantly by clinical profile (age, the presentation of acute myocardial infarction, cardiogenic shock, and multivessel disease) and in-hospital mortality. Understanding the differences in the impact of TARFs on CAD is an important step in improving population-based strategies for CAD prevention.
Open AccessAge-stratified Prevalence and Relative Prognostic Significance of Traditional Atherosclerotic Risk Factors: A Report from the Nationwide Registry of Percutaneous Coronary Interventions in Japan
Background: The prevalence of traditional atherosclerotic risk factors (TARFs) and their association with clinical profiles or mortality in percutaneous coronary intervention (PCI) remain unclear. Methods: The study analyzed 559,452 patients who underwent initial PCI between 2012 and 2019 in Japan. TARFs were defined male, hypertension, dyslipidemia, diabetes, smoking, and chronic kidney disease (CKD). We evaluated the age-specific prevalence of TARFs, and calculated the relative importance (RI) according to R 2 , machine learning to assess the impact of TARFs on clinical profile (age, the presentation of acute myocardial infarction, cardiogenic shock, and multivessel disease) and in-hospital mortality. The average percentage of the RI calculated from these models was defined as the relative contribution (RC) of each TARF. Results: The age-specific prevalence of TARFs, except for CKD, formed an inverted U-shape with significantly different peaks and percentages. Smoking was more prevalent in patients with ST-elevation myocardial infarction than in patients with stable angina (odds ratio [OR], 1.75, 95% confidence interval [CI], 1.73-1.77). In logistic regression model and relative risk model, smoking was most strongly associated with acute myocardial infarction (AMI) (adjusted OR, 1.62, 95% CI, 1.60-1.64; RC, 47.1%) and premature coronary artery disease (adjusted unstandardized beta coefficient [UC], 2.68, 95% CI, 2.65-2.71, RC, 42.2%). Diabetes was most strongly associated with multivessel disease (adjusted UC, 0.068; 95% CI, 0.066-0.070, RC, 59.4%) and the presentation of non-AMI (adjusted OR, 0.77, 95% CI, 0.76-0.78, RI, 21.9%). The absence of dyslipidemia was most strongly associated with presentation of cardiogenic shock (adjusted OR, 0.62; 95% CI, 0.61-0.64, RC, 34.2%) and in-hospital mortality (adjusted OR, 0.44, 95% CI, 0.41-0.46, RC, 39.8%). These specific associations were consistently observed regardless of adjustment or stratification by age. Conclusions: Our analysis showed a significant variation in the age-specific prevalence of TARFs. Further, their contribution to clinical profiles and mortality also varied widely. What is known: Traditional atherosclerotic risk factors (TARFs) are well-established targets for the prevention of adverse cardiovascular events. The impact of TARFs on clinical profiles in the patients with percutaneous coronary intervention remain unclear. What the Study Adds: Due to the prevalence of TARF, which varies by age group, the TARFs that should be actively intervened and educated on will differ for each age group The relative importance of TARF differed significantly by clinical profile (age, the presentation of acute myocardial infarction, cardiogenic shock, and multivessel disease) and in-hospital mortality. Understanding the differences in the impact of TARFs on CAD is an important step in improving population-based strategies for CAD prevention.